Recurrence risk in symptomatic intracranial stenosis treated medically in the real world

The risk of early recurrence in medically treated patients with intracranial atherosclerotic stenosis (ICAS) may differ in clinical trials versus real-world settings. Delayed enrollment may contribute to lower event rates in ICAS trials. We aim to determine the 30-day recurrence risk in a real-world setting of symptomatic ICAS.

Source: Journal of Stroke and Cerebrovascular Diseases - April 6, 2023 Category: Neurology Authors: Shadi Yaghi, Liqi Shu, Eric D. Goldstein, Allison Chang, Narendra Kala, Christoph Stretz, Tina M. Burton, Elizabeth Perelstein, Karen Furie, Mahesh Jayaraman, Radhmer Torabi, Krisztina Moldovan, Adam de Havenon, Pooja Khatri, Mulugeta Gebregziabher, David Source Type: research